Asia-Pacific

Invention has long been regarded as a mental activity that can only originate in human beings. However, with the booming of artificial intelligence (AI) technology in recent years, AI has been endowed with the ability to simulate human mental activities and perform innovative tasks by itself. So far, it is reported that AI technology is capable of conducting scientific experiments, developing technical crafts and completing industrial designs. In the near future, AI is even expected to have the capability to discover natural principles and create fundamental knowledge. Against this background, demands have risen for the protection of AI innovation. In particular, the question being asked is can those inventions solely made by AI "inventors" be protected through filing a patent application and be granted, just like those made by human beings?

In the fourth article from an exclusive series on the automotive industry, Bisman Kaur of Remfry & Sagar discusses brand value in India

Back at the end of April, the Committee of the Science and Technology Innovation Board at the Shanghai Stock Exchange announced that the meeting for reviewing the initial public offering (IPO) application of MEMSensing, a Chinese MEMS microphone sensor supplier, was cancelled due to an "emergence of significant matters." The "significant matters" they were referring to were 16 patent disputes brought by Goertek seeking both permanent injunctions and damages totalling over RMB 100 million ($14.5 million). Goertek and MEMSensing are competitors producing MEMS microphones, a key component in the smart speakers of Google, Amazon, Apple, Alibaba, and Xiaomi.

To strengthen copyright protection, and to implement relevant provisions of the Economic and Trade Agreement between the US and China, on August 5 2020, the Supreme People's Court of the People's Republic of China (the SPC) issued a draft Opinions on Strengthening the Protection of Copyright and Copyright related Rights (关于加强著作权和与著作权有关的权利保护的意见) for public consultation.

Coronil, an ayurvedic drug (formulation of herbs and minerals) developed by Patanjali Ayurved that was initially promoted as a cure for the COVID-19 virus and later approved to be sold as an immunity booster to fight Coronavirus, has run into a controversy. A Chennai-based company Arudra Engineering (Arudra) filed a suit before the Madras High Court, alleging trademark infringement. Arudra sought an injunction restraining Patanjali Ayurved (Patanjali) and Divya Yog Mandir Trust, subsequently impleaded as a defendant, from using the mark "Coronil" or any deceptive variation.

The Indonesian government has established a compulsory licence framework in anticipation of a COVID-19 vaccine. The framework also applies to national defence and security patents.